New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
07:19 EDTBIIB, ELNBiogen price target raised to $170 from $150 at RBC Capital
After Biogen (BIIB) acquired Elan's (ELN) stake in Tysabri, RBC Capital thinks the deal makes sense from a strategic financial perspective, as it will raise Biogen's margins and lower its tax rate. The firm thinks the company's SG&A as a percentage of revenue will also decline following the deal and it maintains an Outperform rating on the shares.
News For BIIB;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 15, 2015
07:29 EDTBIIBOutlook for Biogen trials positive , says RBC Capital
Subscribe for More Information
January 14, 2015
07:05 EDTBIIBIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information
January 13, 2015
13:09 EDTBIIBBiogen CEO says company has strengthened R&D, to stay active in M&A
Subscribe for More Information
January 11, 2015
20:06 EDTBIIBBiogen acquires U.K.-based Convergence for up to $675M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use